These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

176 related items for PubMed ID: 22438097

  • 1. Systemic combination therapy of intravenous continuous 5-fluorouracil and subcutaneous pegylated interferon alfa-2a for advanced hepatocellular carcinoma.
    Uchino K, Obi S, Tateishi R, Sato S, Kanda M, Sato T, Arano T, Enooku K, Goto E, Masuzaki R, Nakagawa H, Asaoka Y, Kondo Y, Yamashiki N, Goto T, Shiina S, Omata M, Yoshida H, Koike K.
    J Gastroenterol; 2012 Oct; 47(10):1152-9. PubMed ID: 22438097
    [Abstract] [Full Text] [Related]

  • 2. Therapeutic efficacy of combination therapy with intra-arterial 5-fluorouracil and systemic pegylated interferon α-2b for advanced hepatocellular carcinoma with portal venous invasion.
    Kasai K, Ushio A, Kasai Y, Sawara K, Miyamoto Y, Oikawa K, Kuroda H, Takikawa Y, Suzuki K.
    Cancer; 2012 Jul 01; 118(13):3302-10. PubMed ID: 22072099
    [Abstract] [Full Text] [Related]

  • 3. Sorafenib plus low-dose cisplatin and fluorouracil hepatic arterial infusion chemotherapy versus sorafenib alone in patients with advanced hepatocellular carcinoma (SILIUS): a randomised, open label, phase 3 trial.
    Kudo M, Ueshima K, Yokosuka O, Ogasawara S, Obi S, Izumi N, Aikata H, Nagano H, Hatano E, Sasaki Y, Hino K, Kumada T, Yamamoto K, Imai Y, Iwadou S, Ogawa C, Okusaka T, Kanai F, Akazawa K, Yoshimura KI, Johnson P, Arai Y, SILIUS study group.
    Lancet Gastroenterol Hepatol; 2018 Jun 01; 3(6):424-432. PubMed ID: 29631810
    [Abstract] [Full Text] [Related]

  • 4. Hepatic arterial infusion of 5-fluorouracil in combination with subcutaneous interferon-alpha for advanced hepatocellular carcinoma.
    Kuroda M, Kobayashi Y, Urawa N, Yamamoto M, Mifuji R, Araki J, Tanaka H, Horiike S, Itani T, Furjita N, Konishi M, Iwasa M, Kaito M, Adachi Y.
    Hepatogastroenterology; 2007 Mar 01; 54(74):518-21. PubMed ID: 17523311
    [Abstract] [Full Text] [Related]

  • 5. Combination therapy of intra-arterial 5-fluorouracil and systemic pegylated interferon α-2b for advanced hepatocellular carcinoma.
    Kasai K, Ushio A, Kasai Y, Sawara K, Miyamoto Y, Oikawa K, Kuroda H, Takikawa Y, Suzuki K.
    Int J Clin Oncol; 2011 Jun 01; 16(3):221-9. PubMed ID: 21132451
    [Abstract] [Full Text] [Related]

  • 6. Arterial infusion of 5-fluorouracil combined with subcutaneous injection of pegylated interferon alpha-2b in treating unresectable hepatocellular carcinoma with portal vein tumor thrombus.
    Wu J, Huang WJ, Wang HY, Wang YF, Peng BG, Zhou Q.
    Med Oncol; 2015 Mar 01; 32(3):65. PubMed ID: 25691293
    [Abstract] [Full Text] [Related]

  • 7. Debulking surgery followed by intraarterial 5-fluorouracil chemotherapy plus subcutaneous interferon alfa for massive hepatocellular carcinoma with multiple intrahepatic metastases: a pilot study.
    Tanaka K, Yabushita Y, Nakagawa K, Kumamoto T, Matsuo K, Taguri M, Endo I.
    Eur J Surg Oncol; 2013 Dec 01; 39(12):1364-70. PubMed ID: 24183169
    [Abstract] [Full Text] [Related]

  • 8. Efficacy of hepatic arterial infusion chemotherapy using 5-fluorouracil and systemic pegylated interferon α-2b for advanced intrahepatic cholangiocarcinoma.
    Kasai K, Kooka Y, Suzuki Y, Suzuki A, Oikawa T, Ushio A, Kasai Y, Sawara K, Miyamoto Y, Oikawa K, Takikawa Y.
    Ann Surg Oncol; 2014 Oct 01; 21(11):3638-45. PubMed ID: 24817369
    [Abstract] [Full Text] [Related]

  • 9. Unresectable colorectal liver metastases: the safety and efficacy of conversion therapy using hepatic arterial infusion immunochemotherapy with 5-fluorouracil and polyethylene glycol-interferon α-2a.
    Nakai T, Okuno K, Kitaguchi H, Ishikawa H, Yamasaki M.
    World J Surg; 2013 Aug 01; 37(8):1919-26. PubMed ID: 23564218
    [Abstract] [Full Text] [Related]

  • 10. Successful treatment of advanced hepatocellular carcinoma by combined administration of 5-fluorouracil and pegylated interferon-alpha.
    Kurokohchi K, Takaguchi K, Kita K, Masaki T, Kuriyama S.
    World J Gastroenterol; 2005 Sep 14; 11(34):5401-3. PubMed ID: 16149157
    [Abstract] [Full Text] [Related]

  • 11. A phase I/II trial of capecitabine combined with peginterferon α-2a in Patients with sorafenib-refractory advanced hepatocellular carcinoma.
    Ogasawara S, Chiba T, Ooka Y, Kanogawa N, Motoyama T, Suzuki E, Tawada A, Kanai F, Yokosuka AO.
    Invest New Drugs; 2014 Aug 14; 32(4):762-8. PubMed ID: 24737402
    [Abstract] [Full Text] [Related]

  • 12. Hepatic resection followed by IFN-alpha and 5-FU for advanced hepatocellular carcinoma with tumor thrombus in the major portal branch.
    Nagano H, Sakon M, Eguchi H, Kondo M, Yamamoto T, Ota H, Nakamura M, Wada H, Damdinsuren B, Marubashi S, Miyamoto A, Takeda Y, Dono K, Umeshit K, Nakamori S, Monden M.
    Hepatogastroenterology; 2007 Aug 14; 54(73):172-9. PubMed ID: 17419255
    [Abstract] [Full Text] [Related]

  • 13. Pretreatment predictor of response, time to progression, and survival to intraarterial 5-fluorouracil/interferon combination therapy in patients with advanced hepatocellular carcinoma.
    Uka K, Aikata H, Takaki S, Miki D, Kawaoka T, Jeong SC, Takahashi S, Toyota N, Ito K, Chayama K.
    J Gastroenterol; 2007 Oct 14; 42(10):845-53. PubMed ID: 17940838
    [Abstract] [Full Text] [Related]

  • 14. Phase II trial of systemic continuous fluorouracil and subcutaneous recombinant interferon Alfa-2b for treatment of hepatocellular carcinoma.
    Patt YZ, Hassan MM, Lozano RD, Brown TD, Vauthey JN, Curley SA, Ellis LM.
    J Clin Oncol; 2003 Feb 01; 21(3):421-7. PubMed ID: 12560429
    [Abstract] [Full Text] [Related]

  • 15. Comparison of hepatic arterial infusion chemotherapy versus sorafenib monotherapy in patients with advanced hepatocellular carcinoma.
    Kawaoka T, Aikata H, Hyogo H, Morio R, Morio K, Hatooka M, Fukuhara T, Kobayashi T, Naeshiro N, Miyaki D, Hiramatsu A, Imamura M, Kawakami Y, Takahashi S, Waki K, Tsuji K, Kohno H, Kohno H, Moriya T, Chayama K.
    J Dig Dis; 2015 Sep 01; 16(9):505-12. PubMed ID: 26121102
    [Abstract] [Full Text] [Related]

  • 16. Combination therapy of intraarterial 5-fluorouracil and systemic interferon-alpha for advanced hepatocellular carcinoma with portal venous invasion.
    Obi S, Yoshida H, Toune R, Unuma T, Kanda M, Sato S, Tateishi R, Teratani T, Shiina S, Omata M.
    Cancer; 2006 May 01; 106(9):1990-7. PubMed ID: 16565970
    [Abstract] [Full Text] [Related]

  • 17. Safety and efficacy of adjuvant pegylated interferon therapy for metastatic tumor antigen 1-positive hepatocellular carcinoma.
    Lee D, Chung YH, Kim JA, Park WH, Jin YJ, Shim JH, Ryu SH, Jang MK, Yu E, Lee YJ.
    Cancer; 2013 Jun 15; 119(12):2239-46. PubMed ID: 23564564
    [Abstract] [Full Text] [Related]

  • 18. Effects of sorafenib combined with low-dose interferon therapy for advanced hepatocellular carcinoma: a pilot study.
    Itokawa N, Atsukawa M, Tsubota A, Okubo T, Arai T, Nakagawa A, Kondo C, Iwakiri K.
    Int J Clin Oncol; 2016 Aug 15; 21(4):676-683. PubMed ID: 26701173
    [Abstract] [Full Text] [Related]

  • 19. Transarterial Infusion of Epirubicin and Cisplatin Combined With Systemic Infusion of 5-Flurouracil Versus Sorafenib for Hepatocellular Carcinoma With Refractoriness of Transarterial Chemoembolization Using Doxorubicin.
    Yoo SH, Kwon JH, Nam SW, Lee JY, Kim YW, Shim DJ, Lee SW, Jang JW.
    Cancer Control; 2020 Aug 15; 27(2):1073274820935843. PubMed ID: 32583687
    [Abstract] [Full Text] [Related]

  • 20. Effective treatment for advanced hepatocellular carcinoma with portal venous invasion using a combination therapy of intra-arterial 5-fluorouracil and subcutaneous pegylated-interferon-alpha-2b.
    Mawatari H, Kirikoshi H, Yoneda M, Higurashi T, Fujita K, Saito S, Inamori M, Takahashi H, Abe Y, Kubota K, Nakajima A.
    Hepatogastroenterology; 2008 Aug 15; 55(86-87):1776-7. PubMed ID: 19102391
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.